


NEUROLOGICAL CONSIDERATIONS IN SICKLE CELL DISEASE & THALASSAEMIA

DR MOIRA DICK AND DR SUE HEIGHT




Neurological Complications in Sickle Cell Disease

- CNS is site of major morbidity in SCD
- Complications include
 - Stroke – event lasting >24 hours +/- new areas of abnormality on scan
 - Silent infarcts
 - Transient ischaemic attacks: resolve <24 hours/no change on imaging
 - Intracranial haemorrhage
 - Cognitive impairment
 - Fits
 - Headaches
 - Visual symptoms – can occur in isolation



Stroke subtype by age



CVA = cerebrovascular accident.

Verduzco LA, et al. Blood. 2009;114:5117-25. © 2009 American Society of Hematology.

Epidemiology of Stroke in SCD

Commonest cause of death in adults in UK (NCEPOD 2008)


- $HbSS > HbS\beta^0 > HbS\beta^+ > HbSC$

Sickle cell anaemia (HbSS): Commonest cause of stroke in children (not neonates)

- 300x more common than in children who do not have HbSS
- Peak incidence at 2-5 years and > 50yrs
- Overall prevalence 4%
- Marked reduction in children since Doppler screening
- 'Silent' Stroke – present 37% by the age of 14 years
- cognitive deficiencies and higher overt stroke risk

Features of Infarctive Stroke in SCD

- Overt strokes
 - Stenosis of intracranial carotid & middle cerebral arteries
 - Progressive vessel occlusion and moyamoya can occur
 - Anterior cerebral circulation
 - Infarction of 'watershed' areas
 - Pathological basis not clear
 - blockage of vasa vasorum
 - 'endothelial damage'
 - Nitric oxide deficiency/free plasma haemoglobin
 - Aggravated by anaemia
- Aneurysms
- Silent Cerebral Infarcts





Stroke



Risk factors for Stroke in SCD

- Previous TIA
 - **Anaemia***
 - **Acute Chest Syndrome in last 2 weeks ***
 - **Rise in Systolic BP***
 - Family History – affected sibling
 - Silent infarcts
 - Nocturnal Hypoxia
 - Children – Transcranial Doppler Velocities**
- *** may occur in inpatients admitted for other reasons**

Transcranial Doppler Scanning (2-16 years – standard of care



Transcranial Doppler Scan (TCD)

- Measurement of blood velocity – detects stenosis
- Age 2-16yrs annual scans
- Ranges defined by STOP study: velocities in
 - middle cerebral arteries (MCA) or
 - distal internal carotid arteries d(ICA)
- Identify those at risk of stroke – primary prevention
 - Normal: < 170 cm/sec
 - Abnormal: >200cm/s
 - Conditional: 170-200cm/s
 - Inadequate: MCA, dICA, bifurcation not seen
 - Abnormal TCD → stroke risk of 10% per year

Primary Prevention of Stroke in SCD

- Stroke Prevention Trial in HbSS (STOP) Study
 - Abnormal TCDs (>200cm/s)
 - 63 assigned transfusions → 1 stroke
 - 67 standard care → 10 strokes, 1 intracerebral bleed
- Optimizing Primary Stroke Prevention in HbSS (STOP 2)
 - children with HbSS, with normal TCDs after >30 months of transfusions for abnormal TCD
 - 41 stopped transfusions → 14 redeveloped abnormal TCDs, and 2 strokes
 - 38 continued transfusion → no abnormal TCDs or strokes



Clinical Presentation of Stroke


- Weakness
- Aphasia
- Seizure
- **Painless** limp
- Subtle/transient motor changes
- Coma
- Can be difficult in young children
- TIA (transient) – symptoms may resolve by time they are seen
- **HIGH INDEX OF SUSPICION**


Diagnosis of Acute Stroke

- History, symptoms and signs
- **Awareness of possibility of diagnosis**
- Urgent imaging
 - CT scan to exclude intracranial haemorrhage/space occupying lesion
 - MRI/MRA with diffusion weighting images
 - Child <8 years may need GA
- If abnormal/deteriorating neurology, or strong clinical suspected **proceed with treatment whilst awaiting scans**

Investigations

- Blood tests urgent
 - FBC & reticulocytes
 - Group and save (will need sickle negative RBCs, ABO and RhD Kell matched)
 - LFTs, U&Es, Glucose, CRP
 - Coagulation screen
 - Consider Malaria Screen, auto-antibodies
 - If not known to King's OR on regular transfusions send HbS%
- Imaging – urgent CT scan
 - ?infarct or bleed ...(or Space Occupying Lesion)






Acute Management of Stroke

- Oxygenation – maintain >96%,
- Adequate hydration –avoid overload
- Regular neurological observations
- Protect airway if necessary
- BP monitoring
- Urgent blood transfusion if Hb <80g/l →100g/l
 - Sickle Negative
 - ABO RhD Kell negative red cells
 - Proceed to urgent exchange transfusion to reduce HbS <30% and increase Hb 12g/l – manual or automated (apheresis).
 - Isovolaemic, avoid fluid shifts, close monitoring


Further management and differential diagnosis to consider

- SALT assessment
- Further imaging/transfusion if continued deterioration
- Consideration of other possible diagnoses, including meningitis, encephalitis, paradoxical embolism
- Rehabilitation
- Further investigations
 - ECHO
 - Sleep Study
 - Neuro-cognitive assessments



Risk of recurrent stroke

- 70% recur in 2 years without transfusion
- 90% reduction of risk with transfusion
- Moya-moya vasculopathy - significant risk even with transfusion
- After 2 years, risk is lower in those who had a prior or concurrent medical illness
- Despite chronic transfusions, overt & silent strokes occur



Platt RW. Hematology. Am Soc Hematol Educ Program. 2006;54-7. Josephson CD, et al. Transfus Med Rev. 2007;21:118-23. Fullerton H, et al. Blood. 2004;104:336-9.

Secondary Prevention of Stroke

- Regular blood transfusion
 - Maintain HbS<30%, Hb>9g/dl
 - Reduces risk of recurrence to about 10%
 - Either: 3-4 weekly top-up transfusions or
 - Automated exchanges (apheresis) 6-8 weekly
- Management of complications of blood transfusion
 - Iron overload → iron chelation - Exjade FCT (or Desferrioxamine)
 - Allo-immunisation
 - Transfusion transmitted infections - immunisations
- Sibling allogeneic bone marrow transplantation
 - HLA type full siblings who do not have HbSS



Deterioration on Regular Transfusion


- ~5-10% children have further strokes despite transfusions
 - 40% suffer further cerebrovascular events - TIAs
 - 20% with moyamoya have further strokes
- Therapeutic options
 - Reduce HbS% <10%
 - Add hydroxyurea
 - Correct overnight hypoxia – oxygen, tonsillectomy
 - Aspirin/dipyridamole (but not in moyamoya)
 - Cerebrovascular bypass procedures

Neovascularisation Surgery

- Surgical techniques established for Moyamoya in Japan
- Several case reports showing benefit in progressive sickle vasculopathy
- Different surgical approaches
 - Encephalo-duro-arteriosynangiosis (EDAS)
 - Extracranial-intracranial bypass


Silent Infarcts ('Silent Strokes')

- Abnormal MRI and no CVA or neurological symptoms >24 hours
- Present in 22% children with HbSS by age 14 years
- Mainly frontal lobes, deep white matter, small vessel disease
- Not clearly linked to large vessel disease or abnormal TCD
- Poor academic attainment
- Increased risk for CVA or new MRI abnormalities
- Seizures
- Headaches
- ?Prevention?



Haemorrhagic Stroke in SCD

- Highest risk in 20-29 year group
 - Cerebral artery aneurysms and MoyaMoya - risk of rupture
 - Multiple, Occur at younger age, common in posterior circulation – develop on background earlier stenosis
 - Overall risk of 0.44 per 100 patient years
 - <20 years: 10% of 1st strokes haemorrhagic vs
 - >20 years: 50% 1st strokes haemorrhagic
 - Mortality 25% - commonest cause of death in adults with SCD
- Associations - more **severe anaemia** and higher WBC
- Presentation - **Stroke, Sudden onset severe headache, seizure**
- Investigation
 - Urgent CT scan
 - MRI/MRA
 - Cerebral angiography
- Management
 - Urgent exchange,
 - Interventional radiology,
 - Neurosurgery



Cognitive Impairment in Sickle Cell Disease

- Significantly reduced IQ in cerebrovascular disease
 - Those with CVAs or Silent infarcts: IQ 77
 - With normal MRI - Reduced IQ mean 4.3 lower than normal
- Reduced employment prospects
 - Higher unemployment
 - Lower mean income than matched population

Neurological Complications in Transfusion-Dependent Thalassaemia (Thalassaemia Major) and Thalassaemia Intermedia

- Cord compression
- Peripheral Neuropathy
- Cognitive Impairment
- Complications of Treatment
 - Chelation therapy – monitoring
 - Desferrioxamine
 - Deferasirox (Exjade)

Visual and Auditory problems

- Can occur in Thalassaemia (or SCD) with iron overload as complication of chelation therapy with Desferrioxamine or Deferasirox (Exjade)
- Can be subclinical before symptoms develop
- Need for regular screening – annual
- Patients told to report problems
- For Desferrioxamine the risk of toxicity related to the therapeutic index
 - Maintain therapeutic Index:

$$\frac{\text{Dose /kg body weight (mg/kg)}}{\text{Ferritin mcg/l}} = <0.025$$

Eyes

- Early changes can be asymptomatic
- Can be irreversible
- Incidence 1.2% (desferrioxamine)
- Importance of screening
- Symptoms – warn patients to report
 - Loss of colour/night vision
 - Loss of acuity/ change in visual fields/central blind spot
- Clinical
 - Cataracts
 - Retinopathy
 - Macula –
 - Assess before treatment and annually




Ears

- High Tone Sensorineural Deafness
- Hearing loss
- Risks in higher doses of chelating agents
- Need annual checks of audiometry – can be irreversible.

Other Neurological complications



- Thalassaemia Intermedia
 - Asymptomatic paravertebral masses – extramedullary haemopoietic tissue
 - Symptoms of Spinal Cord compression,
 - Weakness/Paraesthesiae, Bladder/bowel, Sensory Level
 - Nerve root compression
 - radicular pain, weakness, loss of reflexes
 - May be evident on CXR
 - Urgent MRI spine
 - Emergency –
 - Radiotherapy, hypertransfusion regimen, Hydroxyurea



Summary

- Sickle Cell Disease
 - Cerebrovascular disease – common – starts early
 - Can be 'silent' but with significant morbidity
 - Overt disease can be devastating
 - Aim to prevent by identifying those at risk (TCDs)
 - May modify future presentation in those who have had screening if they have had intervention to stop progression....?
 - Acute episodes can occur in the presence of other illness eg Acute Chest Syndrome, severe anaemia
 - High index of suspicion
 - Investigate and treat urgently
- Thalassaemia
 - Mainly a risk of chelation therapy – hearing and vision
 - Rarely due to under-treatment – extramedullary haemopoiesis
 - Patients need to be told of need to report symptoms and undergo regular screening